Dapagliflozin is a new class of oral hypoglycemic agents. Unlike previous oral hypoglycemic agents, it inhibits the reabsorption of glucose by the renal tubules in the kidneys, so that 90% of the glucose is excreted from the kidneys, i.e., there is a significant increase of sugar in the urine and the blood glucose level in the body decreases. This is why we call this class of drugs inhibitors of sodium-glucose transport proteins 2 (SGLT2). A team of researchers led by John P.H. Wilding of the Department of Obesity and Endocrinology at Aintree University Hospital in Liverpool, UK, designed a 48-week randomized controlled study and continued to observe it for 56 weeks. All subjects were type 2 diabetics with poor glycemic control and were treated with 30 U of insulin per day, with or without up to 2 oral hypoglycemic agents. A total of 808 patients were randomly assigned by computer in a 1:1:1:1 ratio into four groups: control, 2.5 mg of Dapagliflozin, 5 mg of Dapagliflozin, and 10 mg of Dapagliflozin. after 48 weeks, the HbA1c in the group taking Dapagliflozin decreased more than in the control group from – The insulin dose in the Dapagliflozin group remained the same for 48 weeks, and some patients could even reduce their insulin dose by up to 10% and lost weight, while the control group had an increase in both insulin dose and weight. There was no increase in severe hypoglycemia. There were also studies showing an increased chance of urinary tract and genital tract infections in the Dapagliflozin group compared to the glipizide group, especially in women, which was associated with excess sugar excreted in the urine. However, whether there is an increase in bladder and breast cancer is inconclusive, and further studies and expanded sample sizes are needed. Dapagliflozin is a selective inhibitor of sodium-glucose cotransport protein 2 and was developed by Schweppes and AstraZeneca.